Back to top
more

DaVita (DVA)

(Delayed Data from NYSE)

$127.69 USD

127.69
1,118,217

-0.12 (-0.09%)

Updated Aug 7, 2025 04:00 PM ET

After-Market: $127.70 +0.01 (0.01%) 5:52 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value B Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 27% (66 out of 246)

Industry: Medical - Outpatient and Home Healthcare

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Founded in 1994 and headquartered in Denver, CO, DaVita Inc. is a leading provider of dialysis services in the U.S. to patients suffering from chronic kidney failure, also known as end stage renal disease (ESRD). The company operates kidney dialysis centers and provides related medical services primarily in dialysis centers and in contracted hospitals across the U.S. Its services include outpatient dialysis services, hospital inpatient dialysis services and ancillary services such as ESRD laboratory services and disease management services.

Nilanjan Choudhury headshot

5 Stocks to Benefit From Relative Price Strength Trends

by Nilanjan Choudhury

LMB, UI, RCL, DVA and BOOT are five stocks with explosive relative price strength.

Derek Lewis headshot

3 Red Hot Stocks Flashing Buy Signals: DVA, ISRG, SN

by Derek Lewis

Stocks making new highs tend to make even higher highs, particularly when positive earnings estimate revisions hit the tape. And that's precisely what these three companies have seen.

Zacks Equity Research

DaVita Inc. (DVA) Soars to 52-Week High, Time to Cash Out?

by Zacks Equity Research

DaVita HealthCare (DVA) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Zacks Equity Research

Reasons to Retain Inari Medical Stock in Your Portfolio for Now

by Zacks Equity Research

NARI continues to gain from its expanded product portfolio. However, continued loss at the operating level raises concern.

Zacks Equity Research

SYK Stocks Gains Following Expansion of Foot & Ankle Portfolio

by Zacks Equity Research

Stryker unveils two new products, enhancing precision and outcomes in foot and ankle surgeries.

Zacks Equity Research

Factors Driving Veeva Stock More Than 20% in Three Months

by Zacks Equity Research

Robust quarterly results on the back of new partnerships and rising subscription revenues are driving VEEV's shares.

Zacks Equity Research

Here's Why DaVita HealthCare (DVA) is a Strong Value Stock

by Zacks Equity Research

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Zacks Equity Research

DaVita HealthCare (DVA) Gains But Lags Market: What You Should Know

by Zacks Equity Research

In the closing of the recent trading day, DaVita HealthCare (DVA) stood at $153.99, denoting a +0.29% change from the preceding trading day.

Zacks Equity Research

Are Investors Undervaluing DaVita (DVA) Right Now?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Zacks Equity Research

Are Medical Stocks Lagging Adagene (ADAG) This Year?

by Zacks Equity Research

Here is how Adagene Inc. Sponsored ADR (ADAG) and DaVita HealthCare (DVA) have performed compared to their sector so far this year.

Zacks Equity Research

Glaukos Stocks Rides on Strong Product Demand Amid Competition

by Zacks Equity Research

GKOS continues to benefit from a robust product portfolio and a strong pipeline. However, stiff competition remains a woe.

Zacks Equity Research

MASI Stock Down Despite New SafetyNet Deal for Neonatal Care

by Zacks Equity Research

The latest adoption of Masimo's SafetyNet is likely to improve the care provided to premature newborns and facilitate their early discharge from the hospital.

Zacks Equity Research

DaVita HealthCare (DVA) Upgraded to Strong Buy: Here's What You Should Know

by Zacks Equity Research

DaVita HealthCare (DVA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Zacks Equity Research

Here's Why You Should Retain PDCO Stock in Your Portfolio for Now

by Zacks Equity Research

Investors remain optimistic about Patterson Companies on the back of its broad product line.

Zacks Equity Research

Here's Why You Should Retain Glaukos Stock in Your Portfolio Now

by Zacks Equity Research

GKOS continues to benefit from a robust demand for its products as well as expansion in new markets. A strong development pipeline raises optimism.

Zacks Equity Research

VEEV Stock Up Following the Release of New Features of Veeva Site Connect

by Zacks Equity Research

Veeva Systems' Site Connect is likely to aid the sponsors in reducing trial time and expense.

Zacks Equity Research

COO Stock Up 0.4% Following the Launch of New Inserter for Paragard IUD

by Zacks Equity Research

Cooper Companies' latest launch is likely to simplify the insertion process of Paragard IUD, thus making it a more accessible contraceptive choice.

Zacks Equity Research

DaVita and Potlatch have been highlighted as Zacks Bull and Bear of the Day

by Zacks Equity Research

DaVita and Potlatch are part of the Zacks Bull and Bear of the Day article.

Shaun Pruitt headshot

Bull of the Day: DaVita (DVA)

by Shaun Pruitt

Seeing as DaVita's (DVA) growth is also crucial to societal health, its valuation is very intriguing at the moment as the leading provider of kidney care services in the United States.

Zacks Equity Research

Centene's Unit Secures New Four-Year Medicaid Contract in Iowa

by Zacks Equity Research

CNC's unit, Iowa Total Care, wins a new contract to provide Medicaid managed care services, enhancing its presence in Iowa and bringing improved health outcomes in the state.

Zacks Equity Research

DaVita HealthCare (DVA) Up 13% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

DaVita HealthCare (DVA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Shaun Pruitt headshot

Top Medical Stocks to Hedge Against the September Effect

by Shaun Pruitt

Often sought out for defensive protection amid heightened market volatility, medical stocks may be of interest to investors in September which has historically been the most challenging month for stocks.

Zacks Equity Research

DaVita Rallies 44% Year to Date: What's Driving the Stock?

by Zacks Equity Research

DVA's shares gain on the back of strong fundamentals. However, dependence on commercial payers can be a cause of concern.

Zacks Equity Research

DaVita HealthCare (DVA) is a Great Momentum Stock: Should You Buy?

by Zacks Equity Research

Does DaVita HealthCare (DVA) have what it takes to be a top stock pick for momentum investors? Let's find out.

Zacks Equity Research

Catalent's Stock Gains on Q4 Earnings Beat, Gross Margin Up

by Zacks Equity Research

CTLT's solid segmental results led to an encouraging fiscal fourth-quarter performance, driving up share prices in after-hours trading.